<--GAT-->
Clinical Topics

Incidence of NK/T-cell Lymphoma Rises Significantly in the United States

by U.S. Medicine

August 19, 2018

COLUMBIA, SC—Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer/T-cell neoplasms in the United States.

A new study conducted to remedy that lack of information reported in Clinical Lymphoma, Myeloma & Leukemia that rates were rising significantly.1

A study team led by the University of South Carolina School of Medicine and including participation from the VA Nebraska Western Iowa Health Care System performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The researchers estimated the overall survival difference among the subgroups and analyzed the data to determine the factors affecting survival.

They found that, for the 797 patients with NK/T-cell lymphoma, nasal type, the median age at diagnosis was 53 years, and males tended to be younger at diagnosis (P< .0001).

What was surprising was how much diagnosis of the disease had increased, study authors said pointing out that incidence increased from 0.4 in 2001 to 0.8 in 2014 per 1,000,000 individuals, with incidence significantly greater in Hispanic patients compared with that in non-Hispanic patients (rate ratio, 3.03; P= .0001).

The median overall survival, meanwhile, was 20 months (range, 2-73 months) and varied significantly according to the primary site (P< .0001) and the disease stage at diagnosis (P< .0001). NK/T-cell lymphoma patients also had an increased risk of acute myeloid leukemia (standardized incidence ratio, 18.77; 95% confidence interval, 2.27-67.81), the study said.

Specifically for the 105 NK/T-cell leukemia patients, the median age at diagnosis was 58 years (range, 4-95 years), and the overall incidence of the disease was 0.09 per 1,000,000 individuals, although significantly greater in males (rate ratio, 0.41; P< .0001). Unlike NK/T-cell lymphoma, no racial disparities were found in the incidence, researchers pointed out, adding that the median overall survival was 17 months (range, 0-36 months).

“The incidence of NK/T-cell lymphoma, nasal type, in the United States has at least doubled in the past decade, with the greatest predilection among Hispanics,” study authors concluded. “Patients with NK/T-cell lymphoma might have an increased risk of the subsequent development of acute myeloid leukemia.”

1. Kommalapati A, Tella SH, Ganti AK, Armitage JO. Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States. Clin Lymphoma Myeloma Leuk. 2018 Jul;18(7):475-479. doi: 10.1016/j.clml.2018.04.009. Epub 2018 May 4. PubMed PMID: 29752210.


Comments are closed here.


Related Articles

HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation which also pointed out that, although prostate cancer is prevalent in aging... View Article

VA Study Finds No Link Between ADT, Dementia

LA JOLLA, CA—Research has been conflicting on whether androgen deprivation therapy is related to dementia. A research letter in JAMA Oncology pointed out that two studies reported a strong statistically significant association between ADT and... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article

Oncology

Response of Veterans to PD-1 Checkpoint Inhibitors

RENO, NV—The clinical outcomes and the incidence of adverse events for programmed death-1 checkpoint inhibitors in cancer patients at a VA clinic were different from the data that have been published, according to a new... View Article

Oncology

Surgical Staging Often Inadequate for Gallbladder Cancer

Guidelines frequently aren’t followed when it comes to radical cholecystectomy with regional lymphadenectomy for patients with T1b gallbladder cancer.

Oncology

Use of Hospice During Treatment Has Limited VA Use

Unlike in most private sector settings, veterans with advanced cancer can receive hospice care concurrently with treatments such as radiation and chemotherapy.

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up